Introduction {#Sec1}
============

Critical metabolic pathways that are unique to pathogens and are significantly divergent from their hosts are rational targets for the development of new chemotherapeutic agents. In particular, sulfur-containing amino acid metabolism, particularly the de novo L-cysteine biosynthetic pathway, is a promising target for drug development against bacterial and parasitic infections, such as those caused by *Mycobacterium tuberculosis*, *Salmonella typhimurium*, and *Entamoeba histolytica* ^[@CR1]--[@CR6]^.

Amebiasis is an intestinal infection caused by the protozoan pathogen *E*. *histolytica* and is widespread worldwide \[CDC, <https://www.cdc.gov/parasites/amebiasis/index.html>\], particularly in countries with inadequate sewage treatment and poor water quality^[@CR7]^. According to the WHO, an estimated 50 million people are infected with *E*. *histolytica* worldwide, resulting in 40,000--100,000 deaths annually^[@CR8]^. Metronidazole is the drug of choice for treating amebiasis despite its low efficacy against asymptomatic cyst carriers^[@CR1]^. Moreover, metronidazole is also teratogenic and causes adverse side effects, such as nausea, vomiting, headache, insomnia, dizziness, drowsiness and hypersensitivity reactions (urticaria, pruritus, erythematous rash)^[@CR9]^. In addition, *E*. *histolytica* is capable of tolerating sub-therapeutic levels of metronidazole *in vitro* ^[@CR10],[@CR11]^. Therefore, new drugs that target parasite-specific metabolic pathways and enzymes distinct from those targeted by metronidazole are urgently needed.

Sulfur-containing amino acid metabolism in *E*. *histolytica* differs markedly from that in humans with respect to three main features: (i) the absence of forward and reverse transsulfuration pathways and thus does not convert L-methionine to L-cysteine^[@CR12],[@CR13]^ or vice versa; (ii) the presence of a sulfur-assimilatory de novo L-cysteine biosynthetic pathway^[@CR14]--[@CR16]^; and (iii) the presence of a unique enzyme, methionine γ-lyase (MGL), which is involved in the degradation of sulfur-containing amino acids^[@CR17]--[@CR19]^. As MGL and two enzymes involved in the cysteine biosynthetic pathway, serine *O*-acetyltransferase (SAT) and cysteine synthase (CS, *O*-acetylserine sulfhydrylase), are absent in mammals, these enzymes are potential suitable targets for chemotherapeutic agents against amebiasis.

The cysteine biosynthetic pathway plays an important role in the incorporation of inorganic sulfur into organic compounds^[@CR1]^ and has been extensively studied in bacteria, plants, and protozoa^[@CR20]--[@CR24]^. In this pathway, SAT (EC 2.3.1.30) catalyzes the formation of *O*-acetyl-L-serine (OAS) from L-serine and acetyl-CoA^[@CR15],[@CR16]^ (Fig. [1A](#Fig1){ref-type="fig"}). CS \[*O*-acetyl-L-serine (thiol)-lyase\] (EC 4.2.99.8) then catalyzes the production of L-cysteine/S-methylcysteine (SMC) through the modification of sulfide/methanthiol with the alanyl moiety of *O*-acetylserine^[@CR13],[@CR14]^. However, using a metabolomics approach, we previously showed that CS enzymes in *E*. *histolytica* trophozoites cultured in the absence of exogenous L-cysteine are predominantly involved in SMC formation, but not L-cysteine^[@CR13]^. *E*. *histolytica* SAT and CS have several unique features with respect to localization, complex formation and homology. For example, isozymes of SAT (EhSAT1-3) and CS (EhCS1-3) are localized to the cytosol^[@CR14]--[@CR16]^, whereas plant isoforms of SAT and CS are found in the mitochondria, plastids, and cytosol^[@CR25]^. In addition, EhCS1 and EhSAT1 do not form a heteromeric complex^[@CR26]^, whereas bacterial and plant SAT and CS form complexes that are involved in cross-talk between sulfur assimilation, carbon and nitrogen metabolism via the generation of OAS^[@CR27]^. Further, EhSAT1-3 are biochemically divergent, showing 48--73% mutual sequence identity (Fig. [1B](#Fig1){ref-type="fig"}) and markedly different sensitivities to allosteric feedback by L-cysteine^[@CR16]^. EhCS1-3 also exhibit sequence divergence with CS1 and CS2 being identical with the exception of two amino acid changes and CS3 having 83% amino acid identity with CS1 and CS2 (Fig. [1B](#Fig1){ref-type="fig"}).Figure 1Epigenetic repression of cysteine biosynthesis pathway genes in *E*. *histolytica* G3 strain. (**A**) Scheme of the sulfur assimilatory de novo cysteine biosynthetic pathway in *E*. *histolytica*. Abbreviations: SAT, serine O-acetyltransferase (EC 2.3.1.30); CS, cysteine synthase (O-acetyl-L-serine sulfhydrylase, EC 2.5.1.47); and CoA, coenzyme A. (**B**) Percent amino acid identity among *E*. *histolytica* SAT and CS isoforms by ClustalW multiple sequence alignment score. GenBank accession numbers: SAT1, BAA82868; SAT2, XP_650001; SAT3, XP_656373; CS1, XP_650965; CS2, XP_648291; and CS3, XP_653246. (**C**) Semi-quantitative RT-PCR analysis of *SAT1*, *SAT2*, *SAT3*, *CS1* and *CS3* gene transcript levels in trophozoites of strain G3 transfected with either empty vector (psAP2G) or the constructed gene silencing plasmids (psAP2G-SAT1, psAP2G-SAT2, psAP2G-SAT3, psAP2G-CS1 and psAP2G-CS3). cDNA from the generated cell lines (psAP2G, SAT1gs, SAT2gs, SAT3gs, CS1gs and CS3gs) was subjected to 30 cycles of PCR using specific primers for the *SAT1*, *SAT2*, *SAT3*, *CS1* and *CS3* genes. RNA polymerase II served as a control. PCR analysis of samples without reverse transcription was used to exclude the possibility of genomic DNA contamination.

Although the sulfur-assimilatory cysteine biosynthetic pathway in plants, bacteria, and protozoa has been extensively studied and exploited for drug development, the role of individual SAT and CS isozymes and significance of the apparent redundancy of this pathway in *E*. *histolytica* remain to be elucidated. In the present study, we investigated the role of the cysteine biosynthesis pathway in *E*. *histolytica* using parasites in which genes for the enzymes involved in cysteine biosynthesis were silenced by antisense RNA-mediated transcriptional attenuation. Using transcriptomic and metabolomic analyses, we demonstrated that EhCS and EhSAT3 are critical for SMC/cysteine production and cell growth. Furthermore, we examined the fate of SMC unique metabolite in *E*. *histolytica* and revealed that this unique metabolite is involved in the antioxidative stress mechanism.

Results {#Sec2}
=======

Establishment of *CS* and *SAT* gene-silenced strains {#Sec3}
-----------------------------------------------------

To investigate the role of the L-cysteine biosynthesis pathway in *E*. *histolytica*, we utilized antisense small RNA-mediated epigenetic gene silencing to repress the *CS1/2* (CS1 and CS2 are 99% identical at the amino acid level), *CS3*, *SAT1*, *SAT2*, and *SAT3* genes in *E*. *histolytica* strain G3 (Fig. [1C](#Fig1){ref-type="fig"})^[@CR28],[@CR29]^. In the *CS1/2* and *CS3* gene-silenced strains, *CS1/2* and *CS3* gene expression were simultaneously repressed, likely due to the high sequence similarity (83% amino acid identity) between these genes (Fig. [1B](#Fig1){ref-type="fig"}). Similarly, the *SAT1* and *SAT2* genes, whose products share 73% amino acid identity, were simultaneously silenced in the *SAT1* and *SAT2* gene-silenced transformants (Fig. [1B](#Fig1){ref-type="fig"}), whereas the *SAT3* gene was not silenced in either of these transformants because of low (48% at the amino acid level) identity between SAT1 and SAT3 and between SAT2 and SAT3. In the *SAT3* gene-silenced strain, only the *SAT3* gene was silenced (Fig. [1C](#Fig1){ref-type="fig"}), and neither *SAT1* nor *SAT2* was affected. In subsequent analyses, the *SAT1/2* and *CS1/3* gene-silenced transformants, designated SAT1/2gs and CSgs, respectively, were used for further analyses.

Effects of *CS* and *SAT* gene silencing on *E*. *histolytica* growth {#Sec4}
---------------------------------------------------------------------

To examine if the L-cysteine biosynthesis plays a role in the proliferation of *E*. *histolytica*, the growth kinetics of trophozoites of the gene-silenced and control transformants (cell line transfected with psAP2G plasmid) were compared in normal BI-S-33 medium containing 8 mM L-cysteine (Fig. [2A](#Fig2){ref-type="fig"}) or BI-S-33 medium without L-cysteine which we called as L-cysteine lacking medium (Fig. [2B](#Fig2){ref-type="fig"}). However this medium may still contain trace amounts of cysteine from yeast extract and/or tryptone. When cultured in L-cysteine lacking medium, *CS* gene-disrupted transformants displayed a severe growth defect, whereas *SAT3* gene-disrupted transformants showed a mild growth defect (Fig. [2B](#Fig2){ref-type="fig"}). In contrast, SAT1/2gs transformants appeared to grow normally in L-cysteine lacking medium (Fig. [2B](#Fig2){ref-type="fig"}). However, in normal BI-S-33 medium, none of the gene-silenced strains showed defective growth (Fig. [2A](#Fig2){ref-type="fig"}). These results indicate that CS and SAT3 are essential for growth in the absence of exogenous L-cysteine and therefore contribute to cell proliferation.Figure 2Effect of *SAT1/2*, *SAT3* and *CS* gene silencing on the growth of trophozoites cultured under normal (**A**) and L-cysteine lacking (CD) BI-S-33 medium (**B**). Approximately 6000 amoebae in the logarithmic growth phase were inoculated into 6 mL fresh culture medium and amoebae were then counted every 24 h. Data shown are the means ± standard deviations of five biological replicates.

Metabolomic analysis of gene-silenced transformants cultured in normal and L-cysteine lacking BI-S-33 medium {#Sec5}
------------------------------------------------------------------------------------------------------------

A total of 48 intermediary metabolites, including amino acids, nucleotides, and organic acids, were measured by CE-TOFMS-based metabolomic analysis in the SAT1/2gs, SAT3gs and CSgs transformants under different culture conditions (Supplementary Table [S2](#MOESM1){ref-type="media"}). Silencing of the *CS* genes caused drastic changes in the metabolites involved in sulfur-containing amino acid metabolism (Fig. [3](#Fig3){ref-type="fig"}). Specifically, the L-cysteine concentration in CSgs trophozoites was approximately 60% lower than that in control trophozoites when cultured under normal BI-S-33 containing 8 mM L-cysteine and L-cysteine-lacking BI-S-33 medium, consistent with the speculation that CS is involved in L-cysteine production. *CS* gene silencing also resulted in a marked increase in OAS, an activated form of L-serine that is synthesized from L-serine and acetyl-CoA by SAT, in both normal and L-cysteine lacking conditions. In addition, SMC formation was completely abolished by CS gene silencing (Fig. [3](#Fig3){ref-type="fig"}), suggesting that CS enzymes are indispensable for SMC production.Figure 3Effect of *SAT1/2*, *SAT3* and *CS3* gene silencing and L-cysteine depletion on sulfur-containing amino acid metabolism. Levels of metabolites extracted from *SAT1/2*, *SAT3* and *CS* gene silenced (SAT1/2gs, SAT3gs, and CSgs) and control (harboring plasmid psAP2G) strains cultured under normal and L-cysteine lacking (CD) BI-S-33 medium conditions is shown. Data shown are the means ± standard deviations of three biological replicates. In the metabolic pathway schemes, solid arrows represent the steps catalyzed by the enzymes whose encoding genes are present in the *E*. *histolytica* genome, whereas an arrow with a dashed line indicates those likely absent in the genome or not yet identified so far. Abbreviations: RPA, relative peak area; 3PGA, 3-phosphoglycerate; SAH, *S*-adenosylhomocysteine; PGDH, phosphoglycerate dehydrogenase (EC 1.1.1.95); PSAT, phosphoserine aminotransferase (EC 2.6.1.52); PSP, phosphoserine phosphatase (EC 3.1.3.3); MGL, methionine γ-lyase (L-methioninase, EC 4.4.1.11); SAT, serine O-acetyltransferase (EC 2.3.1.30); CS, cysteine synthase (O-acetyl-L-serine sulfhydrylase, EC 2.5.1.47); MAT, methionine adenosyltransferase (S-adenosyl-L-methionine synthetase, EC 2.5.1.6); MT, various methyltransferases (EC 2.1.1.X); and SAHH, adenosylhomocysteinase (S-adenosyl-L-homocysteine hydrolase, EC 3.3.1.1).

In contrast to *CS*, silencing of *SAT1/2* did not markedly alter the levels of sulfur-containing metabolites, particularly OAS, SMC, L-cysteine and L-methionine, in *E*. *histolytica*, suggesting that SAT3 can compensate for the loss of SAT1/2. However, upon silencing of the *SAT3* gene, the levels of SMC and L-cysteine were decreased approximately 40--50% compared to the control strain despite the presence of high levels of the precursor metabolite OAS, which is formed by SAT1 and SAT2 in strain SAT3gs. The reduced level of SMC/cysteine with the concurrent higher OAS level (approximately 60% increase) in strain SAT3gs may be due to a decreased level of CS protein in strain SAT3gs. To investigate this possibility, we examined CS expression at the protein level in the SAT1/2gs, SAT3gs, and control transformant strains. Immunoblot analysis using anti-rEhCS1, anti-rEhCS3, and anti-rEhCPBF1^[@CR30]^ antibodies showed that the relative amounts of these proteins were comparable between these strains (Supplementary Fig. [S1](#MOESM1){ref-type="media"}), suggesting that SAT3 may positively regulate CS activity, but not gene expression or protein stability, whereas SAT1/2 do not regulate CS activity.

Gene silencing of *SAT1/2*, *SAT3*, or *CS1-3* caused global transcriptomic changes {#Sec6}
-----------------------------------------------------------------------------------

To determine if the silencing of the *CS* and *SAT* genes affected the expression of other genes, global gene expression in the SAT1/2gs SAT3gs and CSgs transformants was analyzed using a whole-genome DNA microarray. However, the analysis revealed that after the removal of redundant or obsolete genes (those represented with probe sets with '\_x_at' and those for which corresponding NCBI entries were removed after genome reannotation)^[@CR31]^, only a limited number of genes had three-fold or higher changes in expression (Supplementary Table [S3](#MOESM1){ref-type="media"}).

In CSgs, 34 genes were up-regulated and 25 genes were down-regulated when compared to the control (Table [1](#Tab1){ref-type="table"}). *CS1*-*3* transcript levels were reduced by 104, 128 and 20.4 fold, respectively, in CSgs. Among the genes that were significantly down-regulated included those encoding for several hypothetical proteins (EHI_020830, EHI_196760, and EHI_066720), Rab family GTPase, RabH2^[@CR32]^ (EHI_128180), and a nonpathogenic pore-forming peptide precursor (EHI_169350), which may belong in the saposin-like protein^[@CR31]^ (SAPLIP1) family. In contrast, Ras family GTPase (EHI_074750_at), methylene-fatty-acyl-phospholipid synthase (EHI_153710_at), and deoxyuridine 5′ triphosphate nucleotide hydrolase domain-containing protein (EHI_091670_at) were up-regulated in all three gene-silenced transformants (Supplementary Table [S3](#MOESM1){ref-type="media"}), suggesting that the increased expression of these genes may compensate for the impairment of the cysteine biosynthetic pathway. The most highly upregulated gene related to sulfur metabolism in CSgs was a gene encoding a member of the NADPH-dependent FMN reductase domain-containing protein family (Table [1](#Tab1){ref-type="table"}). Genes encoding NADPH-dependent oxidoreductase 2 (EHI_045340), which was previously shown to be involved in cystine reduction^[@CR33]^, was also upregulated in CSgs strain (Table [1](#Tab1){ref-type="table"}).Table 1List of genes down and up regulated ≥3 fold upon CS gene silencing.ProbeSetIDAccession NumbersCommon NameBasal Expression (log~2~)Fold changeRegulationp-valueEHI_160930_s\_atXM_643199cysteine synthase 211.4127.7down0.000EHI_024230_s\_atXM_645873cysteine synthase 110.4104.3down0.019EHI_060340_atXM_648154cysteine synthase 36.720.4down0.000EHI_020830_s\_atXM_001913952hypothetical protein7.819.9down0.016EHI_128180_s\_atXM_649666Rab family GTPase8.114.9down0.004EHI_196760_s\_atXM_643708hypothetical protein7.710.2down0.005EHI_133210_s\_atXM_001914244peptidase S54 (rhomboid) family protein7.96.1down0.009EHI_169350_atXM_650744nonpathogenic pore-forming peptide precursor, putative7.66.0down0.005EHI_056700_atXM_643998hypothetical protein7.15.1down0.006EHI_066720_atXM_646043hypothetical protein, conserved7.25.0down0.000EHI_161970_atXM_644065leucyl-tRNA synthetase, putative8.74.6down0.009EHI_153670_atXM_651265U1 small nuclear ribonucleoprotein subunit, putative7.94.0down0.004EHI_059870_s\_atXM_647804WH2 domain containing protein9.84.0down0.000EHI_187280_atXM_651366transcription initiation factor SPT5, putative8.73.8down0.015EHI_185620_atXM_644513protein kinase, putative5.73.8down0.033EHI_029600_atXM_644990leucine rich repeat-containing protein7.93.7down0.002EHI_197440_atXM_646593hypothetical protein10.63.6down0.000EHI_180940_atXM_646942lipase, putative4.93.5down0.010EHI_060350_atXM_648153splicing factor Prp8, putative6.93.5down0.016EHI_155220_atXM_643278T-complex protein 1, alpha subunit, putative8.33.4down0.010EHI_065670_atXM_648551cation-transporting P-typeATPase, putative10.83.3down0.019EHI_178610_atXM_651172tyrosine kinase, putative7.63.3down0.047EHI_177660_atXM_650844isoleucyl-tRNA synthetase, putative8.63.2down0.006EHI_005050_atXM_647746sucrose transporter, putative4.53.2down0.039EHI_167130_atXM_649685filopodin, putative9.33.2down0.000EHI_074750_atXM_644490Ras family GTPase5.510.1up0.003EHI_091670_atXM_644055deoxyuridine 5′triphosphate nucleotidohydrolase domain containing protein2.34.9up0.009EHI_126550_atXM_643463AIG1 family protein, putative6.54.6up0.003EHI_022270_s\_atXM_644774NADPH-dependent FMN reductase domain containing protein7.24.5up0.001EHI_159660_atXM_645152hypothetical protein5.94.4up0.005EHI_151780_atXM_652309hypothetical protein2.44.1up0.017EHI_067720_s\_atXM_643101NADPH-dependent FMN reductase domain containing protein7.34.0up0.015EHI_045340_s\_atXM_648481NADPH-dependent oxidoreductases 29.04.0up0.003EHI_022600_s\_atXM_643169NADPH-dependent FMN reductase domain containing protein7.04.0up0.003EHI_134710_atXM_647029hypothetical protein4.44.0up0.013EHI_059320_s\_atXM_001914076hypothetical protein2.63.9up0.024EHI_072960_s\_atXM_001914509deoxyuridine 5′triphosphate nucleotidohydrolase domain containing protein4.33.9up0.010EHI_153710_atXM_001913338methylene-fatty-acyl-phospholipid synthase, putative6.53.9up0.007EHI_182540_atXM_651612Protein tyrosine phosphatases domain containing protein3.83.9up0.000EHI_150660_s\_atXM_642980hypothetical protein3.73.9up0.028EHI_022990_atXM_648401hypothetical protein4.83.8up0.008EHI_174570_atXM_648228hypothetical protein2.33.7up0.001EHI_025710_atXM_644279iron-sulfur flavoprotein, putative5.53.7up0.001EHI_146130_atXM_644793hypothetical protein3.33.7up0.035EHI_046630_atXM_645444Rho family GTPase4.13.7up0.011EHI_172510_atXM_643770acid sphingomyelinase-like phosphodiesterase 3a precursor, putative3.53.6up0.000EHI_174970_atXM_648244hypothetical protein5.43.5up0.010EHI_103260_s\_atXM_001913434NADPH-dependent FMN reductase domain containing protein7.33.5up0.007EHI_181710_s\_atXM_001914510NADPH-dependent FMN reductase domain containing protein7.33.5up0.013EHI_121870_atXM_646700ADP-ribosylation factor 1, putative5.43.5up0.000EHI_069590_atXM_001913469hypothetical protein5.13.4up0.005EHI_125910_atXM_651393double-strand break repair protein MRE11, putative3.13.4up0.006EHI_052130_atXM_650257PQ loop repeat protein4.63.3up0.018EHI_155430_s\_atXM_650657hypothetical protein4.73.3up0.012EHI_001800_atXM_644530hypothetical protein4.73.3up0.019EHI_192550_atXM_001913649hypothetical protein2.33.2up0.009EHI_101260_atXM_651922Ras family GTPase5.63.1up0.008EHI_105080_atXM_648821zinc finger protein, putative8.23.1up0.031EHI_159470_atXM_648174hypothetical protein2.73.0up0.018

In strain SAT1/2gs, 39 genes were up-regulated and 13 genes were down-regulated compared to the control strain (Table [2](#Tab2){ref-type="table"}). The *SAT1* and *SAT2* transcript levels were reduced by 529 and 4.2 fold, respectively, whereas the expression of the *SAT3* gene remained unchanged. The genes encoding phosphoserine aminotransferase (EHI_026360), which catalyzes the formation of L-phosphoserine from 3-phosphohydroxypyruvate in the phosphorylated pathway of L-serine biosynthesis^[@CR34]^, were down-regulated more than five fold (Table [2](#Tab2){ref-type="table"}). Among the most highly upregulated genes was sulfotransferase (EHI_031640), which was up-regulated more than 8 fold, and Fe hydrogenase, which was induced more than 4 fold in strain SAT1/2gs (Table [2](#Tab2){ref-type="table"}). In strain SAT3gs, 16 genes were up-regulated and 19 were down-regulated compared to the control (Table [3](#Tab3){ref-type="table"}). The most highly repressed gene in SAT3gs was SAT3, which had 187-fold lower transcript levels compared the control, whereas *SAT1* and *SAT2* gene expression remained unchanged. Among the genes that were up-regulated by *SAT3* gene silencing were several genes encoding NADPH-dependent FMN reductase domain-containing protein and iron-sulfur flavoprotein (ISF) genes, which were among the most highly up-regulated genes by *CS3* gene silencing (Table [1](#Tab1){ref-type="table"}).Table 2List of genes down and up regulated ≥3 fold upon SAT1/2 gene silencing.ProbeSetIDAccession NumberCommon NameBasal Expression (log~2~)Fold changeRegulationp-valueEHI_202040_atAB023954serine acetyltransferase 112.2528.6down0.002EHI_020830_s\_atXM_001913952hypothetical protein7.811.7down0.001EHI_196760_s\_atXM_643708hypothetical protein7.710.6down0.014EHI_026360_s\_atXM_650291phosphoserine aminotransferase, putative8.55.1down0.004EHI_187090_atXM_651385Rab family GTPase10.84.4down0.007EHI_021570_atXM_644909serine acetyltransferase 24.23.6down0.005EHI_169350_atXM_650744nonpathogenic pore-forming peptide precursor, putative7.63.5down0.024EHI_066720_atXM_646043hypothetical protein, conserved7.23.3down0.000EHI_003950_atXM_643818hypothetical protein8.33.2down0.027EHI_094060_s\_atXM_001913553actin binding protein, putative10.13.2down0.015EHI_199170_s\_atXM_648207hypothetical protein, conserved6.43.1down0.049EHI_183120_s\_atXM_649872centromeric protein E, putative8.03.1down0.014EHI_073980_s\_atXM_648468surface antigen ariel1, putative4.03.0down0.001EHI_031640_atXM_648447sulfotransferase, putative7.58.5up0.000EHI_193640_s\_atXM_643661hypothetical protein2.38.2up0.002EHI_074750_atXM_644490Ras family GTPase5.57.8up0.004EHI_018140_s\_atXM_001914260deoxyuridine 5′-triphosphate nucleotidohydrolase domain containing protein5.56.7up0.002EHI_072960_s\_atXM_001914509deoxyuridine 5′triphosphate nucleotidohydrolase domain containing protein4.36.0up0.007EHI_070690_atXM_001913839Ras GTPase domain conting protein2.35.7up0.020EHI_046630_atXM_645444Rho family GTPase4.15.3up0.005EHI_174970_atXM_648244hypothetical protein5.45.2up0.000EHI_126550_atXM_643463AIG1 family protein, putative6.55.1up0.002EHI_068270_s\_atXM_646627Rho guanine nucleotide exchange factor, putative4.14.9up0.001EHI_146680_s\_atXM_001914548hypothetical protein2.44.8up0.009EHI_004520_atXM_651631hypothetical protein5.14.6up0.013EHI_046040_s\_atXM_645992hypothetical protein5.04.5up0.001EHI_095910_atXM_001913730lipase, putative4.74.4up0.001EHI_134850_atXM_647045Fe-hydrogenase, putative7.54.4up0.011EHI_120580_atXM_646886hypothetical protein3.34.3up0.026EHI_067910_atXM_651687competence protein ComEC, putative6.34.3up0.011EHI_146130_atXM_644793hypothetical protein3.34.1up0.001EHI_151440_atXM_652272cysteine proteinase, putative7.54.1up0.000EHI_182540_atXM_651612Protein tyrosine phosphatases domain containing protein3.84.1up0.001EHI_074580_atXM_645859hypothetical protein3.23.9up0.025EHI_019630_atXM_643344hypothetical protein6.93.9up0.002EHI_123700_atXM_648695hypothetical protein3.73.9up0.019EHI_028940_atXM_645826hypothetical protein8.83.8up0.000EHI_191730_atXM_643923cysteine protease binding protein family 105.33.7up0.017EHI_022990_atXM_648401hypothetical protein4.83.7up0.002EHI_153710_atXM_001913338methylene-fatty-acyl-phospholipid synthase, putative6.53.6up0.007EHI_059320_s\_atXM_001914076hypothetical protein2.63.4up0.037EHI_105080_atXM_648821zinc finger protein, putative8.23.4up0.026EHI_126560_atXM_001914189AIG1 family protein, putative7.53.4up0.004EHI_091670_atXM_644055deoxyuridine 5′triphosphate nucleotidohydrolase domain containing protein2.33.4up0.030EHI_180390_atXM_648725AIG1 family protein, putative9.13.4up0.016EHI_139400_atXM_646219TATA-binding protein-associated phosphoprotein, putative3.73.3up0.002EHI_154270_atXM_645351cell division control protein 42, putative6.13.3up0.008EHI_172510_atXM_643770acid sphingomyelinase-like phosphodiesterase 3a precursor, putative3.53.2up0.000EHI_050570_atXM_651510cysteine proteinase, putative11.33.2up0.001EHI_052130_atXM_650257PQ loop repeat protein4.63.1up0.016EHI_009910_atXM_652020TBC domain containing protein5.63.0up0.011EHI_121750_atXM_646688hypothetical protein5.53.0up0.006 Table 3List of genes down and up regulated ≥3 fold upon SAT3 gene silencing.ProbeSetIDAccession NumberCommon NameBasal Expres-sion (log~2~)Fold changeRegula-tionp-valueEHI_153430_atXM_651281serine acetyltransferase 310.5186.7down0.007EHI_153420_atXM_651282hypothetical protein7.914.0down0.011EHI_196760_s\_atXM_643708hypothetical protein7.712.5down0.004EHI_020830_s\_atXM_001913952hypothetical protein7.87.6down0.002EHI_128180_s\_atXM_649666Rab family GTPase8.16.5down0.004EHI_147860_atXM_646798hypothetical protein5.65.2down0.011EHI_133210_s\_atXM_001914244peptidase S54 (rhomboid) family protein7.95.1down0.011EHI_051430_atXM_652271Ras guanine nucleotide exchange factor, putative5.04.6down0.032EHI_128190_s\_atXM_649665peptidase S54 (rhomboid) family protein5.84.5down0.005EHI_079870_atXM_647774NTP pyrophosphatase domain containing protein7.34.1down0.024EHI_164410_atXM_649301DNA double-strand break repair Rad50 ATPase, putative4.43.9down0.008EHI_111210_atXM_652499DNA double-strand break repair Rad50 ATPase, putative4.23.6down0.000EHI_178130_atXM_646412hypothetical protein8.83.5down0.002EHI_079970_atXM_001913704leucine rich repeat protein, BspA family5.23.2down0.027EHI_005930_atXM_648325hypothetical protein4.13.1down0.011EHI_161970_atXM_644065leucyl-tRNA synthetase, putative8.73.1down0.010EHI_170940_atXM_001913890lipase, putative8.93.1down0.002EHI_074480_s\_atXM_001914032hypothetical protein3.93.0down0.002EHI_054660_atXM_646970apyrase, putative3.93.0down0.047EHI_022600_s\_atXM_643169NADPH-dependent FMN reductase domain containing protein7.08.9up0.002EHI_022270_s\_atXM_644774NADPH-dependent FMN reductase domain containing protein7.28.5up0.002EHI_067720_s\_atXM_643101NADPH-dependent FMN reductase domain containing protein7.38.3up0.001EHI_181710_s\_atXM_001914510NADPH-dependent FMN reductase domain containing protein7.37.9up0.004EHI_103260_s\_atXM_001913434NADPH-dependent FMN reductase domain containing protein7.37.2up0.001EHI_153710_atXM_001913338methylene-fatty-acyl-phospholipid synthase, putative6.55.8up0.002EHI_029930_atXM_001914435hypothetical protein3.64.7up0.003EHI_155430_s\_atXM_650657hypothetical protein4.74.0up0.028EHI_091670_atXM_644055deoxyuridine 5′triphosphate nucleotidohydrolase domain containing protein2.33.9up0.007EHI_146130_atXM_644793hypothetical protein3.33.8up0.000EHI_072960_s\_atXM_001914509deoxyuridine 5′triphosphate nucleotidohydrolase domain containing protein4.33.7up0.011EHI_158010_atXM_645706hypothetical protein4.03.5up0.024EHI_034530_s\_atXM_643791hypothetical protein2.53.4up0.036EHI_074750_atXM_644490Ras family GTPase5.53.4up0.011EHI_198440_s\_atXM_001914343hypothetical protein2.53.3up0.013EHI_018140_s\_atXM_001914260deoxyuridine 5′-triphosphate nucleotidohydrolase domain containing protein5.53.3up0.016

Confirmation of differential gene expression by qRT--PCR {#Sec7}
--------------------------------------------------------

The microarray results were validated by qRT--PCR. Table [4](#Tab4){ref-type="table"} shows a comparison of the qRT-PCR and microarray data of six representative differentially expressed genes identified by the transcriptome analysis, with the RNA polymerase II gene used as reference^[@CR33]^. The results of the qRT-PCR analysis agreed well with the microarray data for all examined gene transcripts (Table [4](#Tab4){ref-type="table"}).Table 4Validation of microarray data by qRT-PCR and microarray analysis.Common NameAccession NumberFold Change by qRT-PCR (by microarray)SAT1/2gsSAT3gsCSgsFe-hydrogenaseXM_6470455.0 (4.4)NDNDSulfotransferaseXM_6484479.1 (8.5)NDNDPhosphoserine aminotransferaseXM_650291−4.6 (−5.1)NDNDNADPH-dependent oxidoreductases 2XM_6484811.4 (1.9)1.3 (1.7)4.7 (4.0)NADPH-dependent FMN reductase domain-containing proteinXM_6431692.4 (3.0)9.4 (8.9)5.1 (4.0)Methylene-fatty-acyl-phospholipid synthaseXM_0019133384.1 (3.6)4.7 (5.8)4.5 (3.9)RNA polymerase IIXM_6439991.2 (1.4)1.2 (1.1)1.1 (1.0)The common names, accession numbers, and fold changes of the selected genes are shown. The values are the fold changes in the expression obtained from qRT-PCR and the corresponding fold changes in the expression values obtained from Affymetrix analysis are shown in parentheses. ND, not detected.

S-Methylcysteine production leads to increased oxidative stress tolerance {#Sec8}
-------------------------------------------------------------------------

To investigate whether the SMC accumulation observed in trophozoites cultured in L-cysteine lacking BI-S-33 medium protects *E*. *histolytica* against oxidative stress, the CSgs, which does not produce SMC and control (harboring plasmid psAP2G) transformants were compared for oxidative stress sensitivity by culturing the two strains in L-cysteine lacking medium. After 48-h cultivation in L-cysteine lacking medium, SMC had accumulated in the control transformant, but remained absent in the CSgs transformant (Fig. [3](#Fig3){ref-type="fig"}). The CSgs and control transformants were next exposed to different concentrations of H~2~O~2~ (0--6.4 mM) for 1 h and viability was then determined. The CSgs transformant showed slightly, but significantly (Student's t-test), lower sensitivity to 0.8--4.0 mM H~2~O~2~ compared to the control transformant, suggesting that CS1--3 or SMC synthesis may be involved in protecting the cells against oxidative stress (Fig. [4](#Fig4){ref-type="fig"}).Figure 4Effect of *CS* gene silencing on oxidative stress tolerance. Trophozoites of CSgs and control (harboring plasmid psAP2G) strains were exposed to different concentrations of H~2~O~2~ for 1 h and viability was then determined. Survival rates are shown as percent of untreated control cells (mean ±S.D. of three independent experiments conducted in triplicate). Statistical comparisons were made by the Student's t test (\*\*P \<0.01, \*\*\*P \<0.001).

Discussion {#Sec9}
==========

The identification and functional characterization of the molecular components involved in essential metabolic pathways contribute to the overall understanding of parasite biology, but also aid in the rational design of novel therapeutics. L-Cysteine is indispensable for the survival of virtually all living organisms and plays a major role in maintaining the redox balance of thiol compounds in microaerophiles^[@CR18]^. The cysteine biosynthetic pathway exists in bacteria, plants, and several parasitic protozoa, including *Leishmania major*, *Trypanosoma cruzi*, and *Trichomonas vaginalis* ^[@CR1]^, and enzymes involved in this pathway are suitable targets for the development of novel drugs to prevent disease caused by these parasites^[@CR2]--[@CR6]^.

In the present study, we investigated the specific role of individual isotypes of SAT and CS using a gene silencing approach. Although SAT^[@CR26]^ and CS^[@CR35]^ have been biochemically^[@CR13]--[@CR16]^ and structurally characterized, the specific role of individual SAT and CS isotypes in proliferation, pathogenesis, and parasitism remains to be elucidated. Although we attempted to silence the expression of single genes, all the three CS isotypes were simultaneously silenced in *E*. *histolytica* due to their high similarity at the nucleotide and amino acid levels (CS1-3, 83--99%). The global repression of CS expression resulted in impaired trophozoites proliferation in L-cysteine lacking BI-S-33 medium, but not in normal BI-S-33 medium containing 8 mM L-cysteine (Fig. [2B](#Fig2){ref-type="fig"}). Metabolomic analysis of the *CS*-silenced transformant under the two culture conditions further revealed that SMC was not detectable and that the level of OAS was markedly reduced, demonstrating that CS is involved in SMC synthesis from OAS (Fig. [3](#Fig3){ref-type="fig"}). We previously showed that *E*. *histolytica* trophozoites produce SMC, rather than L-cysteine, when cultured in L-cysteine lacking BI-S-33 medium^[@CR13]^. The present metabolomic analysis further revealed that L-cysteine levels were also decreased when the CSgs (and SATgs) transformants were cultured in normal BI-S-33 medium containing 8 mM L-cysteine, suggesting that *E*. *histolytica* synthesizes both L-cysteine and SMC, and that the flux towards cysteine synthesis likely depends upon the intracellular availability of sulfides (i.e., methanethiol and sulfide).

In contrast to *CS*, silencing of *SAT1/2* and *SAT3* was specific to the targeted SAT isotypes. Unlike other organisms, *E*. *histolytica* possesses three apparently redundant SAT isozymes^[@CR16]^. These three SAT isotypes differ from one other in their regulatory properties. The isoenzymes SAT1 and SAT2 are regulated through allosteric feedback by L-cysteine^[@CR15],[@CR16]^, whereas SAT3 is relatively insensitive to L-cysteine inhibition^[@CR16]^. Consistent with these findings, EhSAT1-3 showed different levels of sensitivity to allosteric feedback by L-cysteine^[@CR16]^ \[inhibition constant (Ki) values of EhSAT1-3 are 4.7, 28, and 460 μM, respectively\]. We previously showed that under cysteine lacking conditions, OAS and SMC expression levels in *E*. *histolytica* increase, whereas the expression of SAT and CS isotypes are not affected by L-cysteine depletion^[@CR13],[@CR36]^. As OAS and SMC were undetectable under normal conditions, OAS, which is produced by SAT1-3, appears to be readily converted to cysteine, but not SMC. Alternatively, the *in-vivo* activities of SAT3 and cysteine-sensitive SAT1/2 may be repressed by unknown mechanisms. Under cysteine lacking conditions, L-cysteine-sensitive SAT1 and SAT2, together with cysteine-insensitive SAT3, were derepressed, leading to increased production of OAS. The mechanism by which SMC, but not cysteine, accumulates in response to cysteine deprivation in strains SAT1/2gs and SAT3gs remains unknown. However, it is conceivable that in strain SAT1/2gs, SAT3 compensates for the loss of SAT1/2 by producing sufficient cellular OAS and thereby contributes to the maintenance of high SMC levels under cysteine lacking conditions.

Another unique aspect of *E*. *histolytica* SAT1 is the lack of protein-protein interaction with CS^[@CR26]^. It is well known that in bacteria and plants, CS and SAT form a heteromeric complex with a molecular mass of several hundred kilodaltons^[@CR37]^. However, EhCS1 and EhSAT1 form a homodimer and homotrimer, respectively^[@CR26]^, but these proteins do not interact under physiological conditions^[@CR26]^. The lack of interaction between EhCS1 and EhSAT1 was structurally elucidated^[@CR26],[@CR35]^. The apparent reduction of cysteine/SMC production in SAT3gs strain despite high level of OAS may explain the possible formation of a SAT3-CS complex that regulates cellular CS activity. Here, silencing of SAT3 resulted in the loss of complex formation, reduction of CS activity, and decreased production of SMC and L-cysteine (Fig. [3](#Fig3){ref-type="fig"}). Metabolomic analysis confirmed that the similar response occurred in the *CS* gene-silenced transformants. SAT3 possesses a unique 25--30 amino acids extension at the carboxyl terminus and has a low isoelectric point compared to SAT1 and SAT2^[@CR16]^. These features may favor the interaction with *E*. *histolytica* CS, particularly EhCS3, which possesses the highest pI (8.17) among the three CS isotypes. However, this hypothesis needs to be experimentally proven.

The present metabolomic analyses combined with the results of the growth kinetic assay demonstrated that neither the concentrations of OAS, L-cysteine or SMC in the two culture conditions, nor trophozoites growth under L-cysteine lacking conditions were affected by SAT1/2 gene silencing (Fig. [3](#Fig3){ref-type="fig"}). These data suggest that SAT3 is a robust enzyme that likely compensated for the loss of SAT1/2 under *in-vitro* conditions. In contrast to SAT1/2, repression of SAT3 had more marked effects on growth than the repression of SAT1/2, suggesting that SAT3 is critical for survival under stressful conditions, whereas SAT1/2 are involved in more general house-keeping roles. This speculation is also supported by the fact that the levels of both L-cysteine and SMC were decreased in strain SAT3gs.

To determine whether other genes, particularly those involved in sulfur metabolism, compensate for the loss of CS and SAT gene expression, we compared the transcriptomes of the CSgs, SAT1/2, SAT3gs, and control strains grown in normal medium. Notably, several genes from a family of the NADPH-dependent FMN reductase domain-containing proteins, also known as iron-sulfur flavoproteins (ISFs), which are commonly found in anaerobic prokaryotes, were highly upregulated in CSgs and SAT3gs (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}). To date, the only eukaryotic species that have been found to possess ISF homologs are *E*. *histolytica* and *Trichomonas vaginalis* ^[@CR38],[@CR39]^. A search of the genome database of *E*. *histolytica* revealed the presence of seven independent ISF genes^[@CR40]^, which were previously shown to be upregulated in *E*. *histolytica* cells cultured in L-cysteine lacking BI-S-33 media, suggesting that these genes are regulated in response to L-cysteine deprivation^[@CR36]^.

In contrast to CSgs strain, we found that in SAT1/2 gene-silenced strain one of the sulfotransferase, *SULT9* (XP_653539, EHI_031640) (Table [2](#Tab2){ref-type="table"}), was up-regulated more than eight fold, suggesting its involvement in L-cysteine biosynthesis and/or redox-related metabolism. The *E*. *histolytica* genome contains 10 genes that encode putative sulfotransferases (SULTs), which are localized in the cytosol and are involved in the production of sulfated molecules^[@CR41]^. For example, *SULT6* (XP_649714, EHI_146990) is responsible for synthesizing cholesteryl sulfate, an important compound for the encystation process in the *Entamoeba* life cycle^[@CR41]^. However, the function of other SULTs in *E*. *histolytica* remains largely unknown. In *Arabidopsis* roots, a plasma membrane sulfate ion transporter (SULTR) physically interacts with CS to coordinate internalization of sulfate ions based on the energetic/metabolic state of root cells^[@CR42]^. Here, we also determined that Fe hydrogenase, which belongs to a distinct class of hydrogen-producing metalloenzymes and is found in a wide variety of prokaryotes and eukaryotes^[@CR43]^, was up-regulated more than four fold in strain SAT1/2gs. Fe hydrogenase contributes to the utilization of hydrogen as a growth substrate and for the disposal of excess electrons through combination with protons to form hydrogen^[@CR43]^. Although the role of Fe hydrogenase in *Entamoeba* is unclear, it is possible that this enzyme is regulated in response to oxygen levels, as was shown in *Chlamydomonas reinhardtii*, which contained increased transcript levels of Fe hydrogenase upon shifting from an aerobic to anaerobic atmosphere^[@CR44]^.

The present metabolome data of strain CSgs suggest that in addition to L-cysteine, CS enzymes are involved in SMC production (Fig. [3](#Fig3){ref-type="fig"}). SMC is a sulfur-containing amino acid that is found in relatively large amounts in several legumes, where it is considered to be a sulfur storage compound^[@CR45]^. However, the fate and physiological significance of SMC in protozoa, particularly *E*. *histolytica*, is not yet fully understood. Previously, we investigated metabolic responses to hydrogen peroxide - and paraquat-mediated oxidative stress in *E*. *histolytica* trophozoites and reported that SMC levels are increased more than two fold under both stress conditions^[@CR46]^, suggesting the involvement of this metabolite in the oxidative stress response. To confirm this speculation, we compared the oxidative stress tolerance between the control and CSgs transformant because SMC was undetected in CSgs strain (Fig. [3](#Fig3){ref-type="fig"}), and demonstrated that the CSgs transformant was more sensitive to oxidative stress. In *Brassica* exposed to H~2~O~2~ or O~2~ stress, SMC is non-enzymatically converted to SMC sulfoxide^[@CR47]^, which is further enzymatically catabolized into pyruvate, ammonia, and alkylthiosulfinates^[@CR48]^. The enzyme that catalyzes the last reaction is cystine lyase (EC 4.4.1.8) and behaves similarly to allinase (EC 4.4.1.4) in garlic, with the exception that cystine lyase also has the ability to cleave L-cystine^[@CR49]^. Based on this observation, we propose that under oxidative stress conditions, SMC is converted to SMC sulfoxide and is further degraded by a lyase enzyme, such as methionine γ-lyase^[@CR17]^ (MGL), to pyruvate and sulfenic acid.

In summary, the present metabolomic analysis revealed that CS and SAT3 are key enzymes for cysteine/SMC production in *E*. *histolytica* and are also essential for parasite survival under oxidative stress conditions. Transcriptomic analysis of the constructed CSgs and SAT3gs strains revealed that compensatory mechanisms in which ISFs play key roles operate under conditions where the CS and SAT3 pathway(s) are inactivated. These findings corroborate the metabolic and physiological importance of the L-cysteine pathway in *E*. *histolytica* and suggest that CS and SAT3 represent good targets for drug development. Further work is needed to demonstrate the specific role of these ISFs in *E*. *histolytica*.

Methods {#Sec10}
=======

Microorganisms and cultivation {#Sec11}
------------------------------

*In-vitro* cultures of *E*. *histolytica* strains HM-1:IMSS cl6 and G3 were routinely maintained in Diamond's BI-S-33 medium at 35.5 °C, as described previously^[@CR50],[@CR51]^.

Gene silencing {#Sec12}
--------------

Strain G3 and plasmid psAP2 were kindly provided by Dr. David Mirelman (Weisman Institute, Israel)^[@CR28],[@CR29]^. Gene silencing was performed as previously described^[@CR28],[@CR29],[@CR36],[@CR52]^. Briefly, 420-bp fragments containing the entire open reading frames of the *E*. *histolytica CS1*, *CS3*, *SAT1 SAT2* and *SAT3* genes starting at the initiation codon were amplified by PCR from cDNA using the oligonucleotide primers listed in Supplementary Table [S1](#MOESM1){ref-type="media"}. The obtained PCR products were digested with StuI and SacI and inserted into StuI/SacI-digested pSAP2G to produce psAP2G-CS1, psAP2G-CS3, psAP2G-SAT1, psAP2G-SAT2 and psAP2G-SAT3. The constructed plasmids were introduced into *E*. *histolytica* strain G3 by liposome-mediated transfection^[@CR15]^, and the resulting transformants (designated psAP2G \[control\], CS1gs, CS3gs, SAT1gs, SAT2gs and SAT3gs) were selected and maintained in normal BI-S-33 medium supplemented with 7 μg/ml geneticin (Invitrogen). The expression of the respective genes was confirmed by semi-quantitative RT-PCR as described previously using RNA polymerase II mRNA (GenBankTM accession number XM_643999) as a reference^[@CR33]^, as the expression of this gene was invariant in all of the transformants. The transformants were designated psAP2G (control), CS1gs, CS3gs, SAT1gs, SAT2gs and SAT3gs.

Extraction of metabolites from *E*. *histolytica* {#Sec13}
-------------------------------------------------

*E*. *histolytica* trophozoites were cultured for approximately 24 h in standard BI-S-33 medium containing 8 mM L-cysteine. The medium was replaced with either normal BI-S-33 medium or medium lacking L-cysteine^[@CR13]^, and trophozoites were cultured for a further 48 h. To extract metabolites, approximately 1.5 × 10^6^ cells were then harvested and immediately suspended in 1.6 mL of −75 °C methanol to quench metabolic activity. To minimize the effects of experimental artifacts, such as ion suppression, on metabolite levels, 2-(N-morpholino) ethanesulfonic acid, methionine sulfone, and D-camphor-10-sulfonic acid were added to each sample as internal standards^[@CR13],[@CR53],[@CR54]^. The samples were sonicated for 30 s and then mixed with 1.6 mL chloroform and 640 µl deionized water. After vortexing, the mixed samples were centrifuged at 4600 g for 5 min at 4 °C. The aqueous layer (1.6 mL) was filtrated using an Amicon Ultrafree-MC ultrafilter (Millipore Co., Massachusetts, USA) and the collected sample was centrifuged at 9100 g at 4 °C for approximately 2 h. The filtrate was vacuum dried and stored at −80 °C until needed for mass spectrometric analysis^[@CR55]^. Prior to the analysis, the sample was dissolved in 20 μl de-ionized water containing 200 μmol/L of two reference compounds (3-aminopyrrolidine and trimesic acid).

Instrumentation and capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS) {#Sec14}
-----------------------------------------------------------------------------------------

CE-TOFMS was performed using an Agilent CE Capillary Electrophoresis System equipped with an Agilent 6210 Time-of-Flight mass spectrometer, Agilent 1100 isocratic HPLC pump, Agilent G1603A CE-MS adapter kit, and Agilent G1607A CE-ESI-MS sprayer kit (Agilent Technologies, Waldbronn, Germany). The system was controlled by Agilent G2201AA ChemStation software for CE. Data acquisition was performed using Analyst QS software for Agilent TOF (Applied Biosystems, CA, USA; MDS Sciex, Ontario, Canada).

CE-TOFMS conditions for cationic metabolite analysis {#Sec15}
----------------------------------------------------

Cationic metabolites were separated in a fused-silica capillary (50 μm i.d. × 100 cm total length) filled with 1 mol/L formic acid as the reference electrolyte^[@CR56]^. Sample solution (\~3 nL) was injected at 50 mbar for 3 s, and a positive voltage of 30 kV was applied. The capillary and sample trays were maintained at 20 °C and below 5 °C, respectively. Sheath liquid composed of methanol/water (50% v/v) and 0.1 μmol/L hexakis (2,2- difluorothoxy) phosphazene was delivered at 10 μL/min. ESI-TOFMS was operated in positive ion mode. The capillary voltage was set at 4 kV and the flow rate of nitrogen gas (heater temperature 300 °C) was set at 10 psig. For TOFMS, the fragmenter voltage, skimmer voltage, and octapole radio frequency voltage (Oct RFV) were set at 75, 50, and 125 V, respectively. An automatic recalibration function was performed using the masses of two reference compounds, protonated 13C methanol dimer (m/z 66.063061) and protonated hexakis (2,2-difluorothoxy) phosphazene (m/z 622.028963), which provided the lock mass for exact mass measurements. Exact mass data were acquired at the rate of 1.5 cycles/s over 50 to 1,000 m/z.

CE-TOFMS conditions for anionic metabolite analysis {#Sec16}
---------------------------------------------------

Anionic metabolites were separated in a cationic-polymer--coated COSMO(+) capillary (50 μm i.d. × 110 cm) (Nacalai Tesque) filled with a 50 mmol/L ammonium acetate solution (pH 8.5) as the reference electrolyte^[@CR57],[@CR58]^. Sample solution (\~30 nL) was injected into the system at 50 mbar for 30 s and a negative voltage of −30 kV was applied. Ammonium acetate (5 mmol/L) in methanol/water (50% v/v) containing 0.1 μmol/L hexakis (2,2-difluorothoxy) phosphazene was delivered as sheath liquid at 10 μL/min. ESI-TOFMS was performed in negative ion mode at a capillary voltage of 3.5 kV. For TOFMS, the fragmenter voltage, skimmer voltage, and Oct RFV were set at 100, 50, and 200 V, respectively^[@CR58]^. An automatic recalibration function was performed using the masses of two reference compounds: deprotonated 13C acetate dimer (m/z 120.038339) and an acetate adduct of hexakis (2,2-difluorothoxy) phosphazene (m/z 680.035541). The other conditions were identical to those used for the cationic metabolome analysis.

CE-TOFMS data processing {#Sec17}
------------------------

Raw data were processed using in-house Masterhands software^[@CR59]^. The overall data processing flow consisted of the following steps: noise-filtering, baseline-removal, migration time correction, peak detection, and peak area integration from a 0.02 m/z-wide slice of the electropherograms. The data processing resembled the common strategies used for LC-MS and GC-MS data analysis software, such as MassHunter (Agilent Technologies) and XCMS^[@CR60]^. Accurate m/z values for each peak were calculated by Gaussian curve fitting in the m/z domain, and migration times were normalized using alignment algorithms based on dynamic programming^[@CR61],[@CR62]^. All target metabolites were identified by matching their m/z values and normalized migration times with those of standard compounds in the in-house library.

RNA isolation and Affymetrix microarray hybridization {#Sec18}
-----------------------------------------------------

Trophozoites were grown in BI-S-33 medium containing 8 mM L-cysteine for approximately 48 h. The collected cell pellets were resuspended in Trizol reagent (Invitrogen, Carlsbad, CA, USA) and RNA was isolated according to the manufacturer's protocol. The RNA concentration for each sample was measured using a Nanodrop Spectrophotometer 1000 (Thermo Scientific, Wilmington, DE, USA). RNA integrity was checked using an Experion Automated Electrophoresis System (RNA StdSens analysis kit, Bio-Rad). All reagents and protocols followed those described in the Affymetrix user manuals. Using the One-Cycle cDNA synthesis kit, 5 μg total RNA was reverse transcribed using a T7-Oligo (dT) primer for first strand cDNA synthesis. After second strand synthesis, the double-stranded cDNA template was used for *in-vitro* transcription (IVT) in the presence of biotinylated nucleotides (GeneChip IVT labeling kit) to produce Biotin-labeled cRNA. Unincorporated NTPs were removed from the biotinylated cRNA (GeneChip sample cleanup module), which was then purified, quantified and fragmented. A hybridization cocktail consisting of eukaryotic hybridization controls and fragmented, labeled cRNA (GeneChip Hybridization, Wash and Stain Kit) were hybridized for 16 h at 45 °C in a Hybridization Oven 640 (Affymetrix) onto a custom-generated Affymetrix platform microarray (49--7875) with probe sets consisting of 11 probe pairs, each representing 12,384 *E*. *invadens* ^[@CR63]^ (Eh_Eia520620F_Ei) and 9,327 *E*. *histolytica* ^[@CR36]^ (Eh_Eia520620F_Eh) open reading frames. The array chips were washed and stained (GeneChip Hybridization, Wash and Stain Kit) with Streptavidin--phycoerythrin Biotinylated anti-streptavidin antibody using a GeneChip Fluidics Station 450 (Affymetrix) for 1.5 h. After washing and staining, the GeneChip arrays were scanned using a Hewlett-Packard Affymetrix Scanner 3000.

Analysis of microarray data {#Sec19}
---------------------------

A minimum of two arrays was used for each test condition. Raw probe intensities were generated using Gene Chip Operating Software (GCOS) and the Gene Titan Instrument from Affymetrix. Normalized expression values for each probe set were obtained from R 2.7.0 downloaded from the Bioconductor project (<http://www.bioconductor.org>) using robust multiarray averaging with correction for oligosequence (gcRMA). Standard correlation coefficients were calculated using GeneSpring GX 10.0.2. One-way ANOVA analysis with Tukey's Post Hoc test was performed to extract differentially expressed genes. P values were calculated using Welch's t-test after multiple test correction by the Benjamini--Hochberg method. A post-hoc test using Tukey's Honestly Significant Difference test was conducted to determine significant differences between samples.

Quantitative real-time PCR (qRT--PCR) {#Sec20}
-------------------------------------

Total RNA extracted above were used for qRT--PCR. cDNA synthesis was performed using the SuperScript III First-Strand Synthesis System (Invitrogen) following the manufacturer's instructions. cDNA was synthesized from 5 μg total RNA and oligo (dT) 20 primers using the Superscript III First-Strand Synthesis System (Invitrogen). PCR was performed with cDNA as the template and gene-specific primers using the ABI PRISM 7300 Sequence Detection System (Applied Biosystems, Weiterstadt, Germany). The genes whose expression was verified by qRT--PCR are listed in Supplementary Table S[4](#MOESM1){ref-type="media"}. The RNA polymerase II gene was used as a control. The parameters for PCR were: an initial denaturation step at 95 °C for 9 min followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 50 °C for 30 s and extension at 65 °C for 1 min. A final step at 95 °C for 9 s, 60 °C for 9 s and 95 °C for 9 s was used to remove primer dimers. All test samples were run in triplicate. An RT-negative control was also used for each sample set along with a blank control consisting of nuclease-free water in place of cDNA.

Growth assay of *E*. *histolytica* trophozoites {#Sec21}
-----------------------------------------------

A cell-growth assay was performed as described previously^[@CR36]^. Briefly, approximately 6 × 10^4^ exponentially growing SAT1/2, SAT3, or CS gene-silenced trophozoites and control transformants were inoculated into 6 mL normal BI-S-33 medium with and without L-cysteine supplemented with 7 μg/mL geneticin, and the number of parasites was counted every 24 h using a haemocytometer.

Hydrogen peroxide (H~2~O~2~) sensitivity assay {#Sec22}
----------------------------------------------

To examine sensitivity to H~2~O~2~, *E*. *histolytica* CS gene-silenced and control (harboring plasmid psAP2G) transformants were cultured in L-cysteine lacking BI-S-33 media containing 7 μg/mL geneticin for 48 h at 35.5 °C. After 48 h, approximately 10^4^ trophozoites per well were seeded into the wells of a 96-well plate containing BI-S-33 medium supplemented with 7 μg/mL geneticin and further incubated for 1 h at 35.5 °C. The trophozoites were then exposed to H~2~O~2~ (0, 0.8, 1.6, 2.4, 3.2, 4, 4.8 and 6.4 mM) for 1 h. After incubation, the medium was removed and 90 μl of pre-warmed Opti-MEM I (Life Technologies) and 10 μl WST-1 solution^[@CR64]^ (Roche Diagnostics, Mannheim, Germany) were added to each well. Viability of trophozoites was detected by measuring absorbance at 450 nm using a microplate reader (Model 550, Bio-Rad, Tokyo, Japan). The sensitivity assays were performed in triplicate and repeated at least three times.

Electronic supplementary material
=================================

 {#Sec23}

Supplementary Fig. S1 Dataset 1 Dataset 2 Dataset 3 Dataset 4

**Electronic supplementary material**

**Supplementary information** accompanies this paper at 10.1038/s41598-017-15923-3.

**Publisher\'s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work was supported in part by a grant for Research on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research on Innovative Areas (23117001, 23117005), a Grant-in-Aid for Scientific Research (23390099) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and a grant for Science and Technology Research Partnership for Sustainable Development from AMED and the Japan International Cooperation Agency to TN.

G.J. and T.N. conceived and designed the experiments. G.J. and D.S. performed the experiments. G.J. analyzed the data. T.N. and T.S. contributed reagents/materials/analysis tools. G.J. and T.N. wrote the paper. All authors reviewed the manuscript prior to submission.

Competing Interests {#FPar1}
===================

The authors declare that they have no competing interests.
